MRK - Merck & Co., Inc.

NYSE - NYSE Delayed Price. Currency in USD
62.52
+0.01 (+0.02%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close62.51
Open62.06
Bid0.00 x 0
Ask0.00 x 0
Day's Range62.01 - 62.54
52 Week Range52.83 - 66.41
Volume6,877,574
Avg. Volume9,856,355
Market Cap168.198B
Beta1.06
PE Ratio (TTM)108.54
EPS (TTM)0.58
Earnings DateJul 27, 2018
Forward Dividend & Yield1.92 (3.09%)
Ex-Dividend Date2018-06-14
1y Target Est69.44
Trade prices are not sourced from all markets
  • Merck touts a 60% price cut, but the drug is outdated and on the way out
    MarketWatch10 hours ago

    Merck touts a 60% price cut, but the drug is outdated and on the way out

    Drugmakers have been lining up to tout new drug price policies lately, from deferring increases to freezing drug prices. Merck & Co. Inc. went a step further on Thursday, announcing a cap on average increases and cuts to some drug prices. The largest percentage cut announced was a 60% price reduction for its Zepatier treatment for hepatitis C.

  • See what the IHS Markit Score report has to say about Merck & Co Inc.
    Markit2 days ago

    See what the IHS Markit Score report has to say about Merck & Co Inc.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. Over the last one-month, outflows of investor capital in ETFs holding MRK totaled $1.32 billion.

  • Reuters2 days ago

    Swiss, German drugmakers join U.S. price freeze

    European drugmakers Roche , Bayer and Merck KGaA became the latest companies to freeze prices in the United States for the rest of 2018 following criticism by President Donald Trump over the cost of medicine. Roche did boost U.S. prices for nine key drugs by an average of 3 percent on July 1, but said it would hold off additional increases as discussions with the Trump administration continue over a longer-term solution to containing healthcare costs.

  • Benzinga2 days ago

    Merck Announces Plans To Cut Drug Prices

    Last week, Pfizer Inc. (NYSE: PFE) announced plans to restructure the company and plans to deter price increases for as long as possible, assuming that Trump makes some changes. Merck announced Thursday that it will lower the price of several medications while also limiting future price increases. The price of several medications will drop by 10 percent, including Prinivil, Remeron and Trusopt, according to Merck.

  • Roche Hiked Cancer-Drug Prices Before Pledge to Keep Them Flat
    Bloomberg2 days ago

    Roche Hiked Cancer-Drug Prices Before Pledge to Keep Them Flat

    Like a growing number of its peers, Roche Holding AG pledged this week not to raise drug prices for the rest of the year. Roche gave the U.S. government its no-price-rises promise on July 11, the company said in a statement Friday. The health system also needs to focus on “long-term, system-wide solutions that lower costs,” Roche said.

  • Reuters2 days ago

    Swiss, German drugmakers join U.S. price freeze

    European drugmakers Roche (ROG.S), Bayer (BAYGn.DE) and Merck KGaA (MRCG.DE) became the latest companies to freeze prices in the United States following criticism by the Trump administration of the cost of medicine. Roche, Bayer and Merck KGaA all said on Friday they would not seek to lift prices this year in the world's biggest drug market, following Novartis (NOVN.S), Pfizer (PFE.N) and U.S. drugmaker Merck (MRK.N) which had already announced similar moves.

  • Stanley Black & Decker release earnings, State Street goes shopping, Starbucks opens 'signing store'
    Yahoo Finance2 days ago

    Stanley Black & Decker release earnings, State Street goes shopping, Starbucks opens 'signing store'

    Stanley Black & Decker, Microsoft, State Street, Merck and Starbucks are the companies to watch.

  • Merck to Cut Price of Few Drugs Amid Drug Pricing Controversy
    Zacks2 days ago

    Merck to Cut Price of Few Drugs Amid Drug Pricing Controversy

    Merck (MRK) announces a 60% cut in U.S. list prices for its hepatitis C drug, Zepatier. It will also lower the list price of some other drugs by 10%.

  • Better Buy: Eli Lilly and Company vs. Merck & Co.
    Motley Fool3 days ago

    Better Buy: Eli Lilly and Company vs. Merck & Co.

    Which stock wins in a one-on-one matchup between these two big drugmakers?

  • Motley Fool3 days ago

    Eli Lilly Scores a Win in Diabetes

    A new study may give sales of one of its diabetes drugs a boost.

  • The Wall Street Journal3 days ago

    [$$] Merck to Limit Drug-Price Increases, Cut Some Prices

    Merck & Co. said Thursday it will cut U.S. list prices for several of its drugs including the hepatitis C treatment Zepatier, and the company pledged to limit future net price increases. Merck, based in Kenilworth, N.J., said it was cutting prices “to help reduce patient out-of-pocket costs.” The price cuts will go into effect in the fall, a spokeswoman said.

  • Reuters3 days ago

    Merck lowers prices of some drugs after Trump calls out industry

    Merck & Co on Thursday announced price cuts to some of its medicines, including a 60 percent reduction to a hepatitis C treatment, after U.S. President Donald Trump criticized drugmakers for failing to help reduce healthcare costs for consumers. Amid heightened political scrutiny over the high cost of prescription medicines and promises by Trump that drug price reductions were coming, New Jersey-based Merck became the first major drugmaker to announce voluntary price decreases. In addition to slashing the price of Zepatier, which owns a very small share of the hepatitis market, Merck said it would lower the list price by 10 percent of six other older drugs with minuscule sales.

  • MarketWatch3 days ago

    Merck to lower price of Hep C treatment Zepatier by 60%, commits to 'responsible' pricing

    Merck & Co. Inc. (mrk) said Thursday it is adopting a 'responsible' pricing policy and will cut the prices of certain products, while committing to increasing the average price of its drugs by no more than the annual inflation rate. The high price of drugs has been a controversial topic in the last few years and one that President Donald Trump has pledged to address. Merck said it will reduce the price of its Zepatier treatment for Hepatitis C by 60%, and will lower other prices by 10%.

  • Business Wire3 days ago

    Merck Reinforces Commitment to Responsible Pricing

    Merck (MRK), known as MSD outside the United States and Canada, has a long history of responsible pricing. In 2017, Merck issued its second annual Pricing Action Transparency Report, which showed that net prices across Merck’s U.S. product portfolio declined by 1.9 percent. The Merck products selected were based on a range of factors including the gap between list price and actual discounted (net) prices paid in the market, the contractual obligations under existing arrangements with payers, and the opportunity to broaden access to treatment.

  • Why Investors Are Excited about Advaxis
    Market Realist3 days ago

    Why Investors Are Excited about Advaxis

    Advaxis (ADXS), in collaboration with Merck & Co. (MRK), is conducting a Phase 1 Part 2 trial to evaluate the safety and efficacy of ADXS-PSA as a monotherapy and in combination with Merck’s Keytruda in patients with previously treated metastatic, castration-resistant prostate cancer. In the trial, 13 patients were evaluated on monotherapy and 37 patients were evaluated on combination therapy. The safety profile was found to be consistent with prior clinical studies that used Lm Technology.

  • See what the IHS Markit Score report has to say about Merck & Co Inc.
    Markit4 days ago

    See what the IHS Markit Score report has to say about Merck & Co Inc.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. MRK credit default swap spreads are within the middle of their range for the last three years.

  • Investopedia6 days ago

    Analysis: Motivating Factors Behind Pfizer’s Big Split

    Pfizer, the worlds second largest pharmaceutical company, announced on Wednesday, July 11th, plans to split into three separate businesses in a major restructuring move. The Innovative Medicines division will bring in most of Pfizer’s revenue. In a press release, the company said that the growth potential for that business is strongest in part because of the aging population which will increase the demand for new medicines.

  • The Wall Street Journal7 days ago

    [$$] Startup Producing Cell-Grown Meat Raises New Funding

    and a top European meat processor are backing a startup producing beef from cattle cells, ramping up a race to transform the global meat industry with cell-culture technology. fuels a continuing effort to fulfill growing global demand for meat via a process that developers say requires a fraction of the resources used in traditional livestock and poultry production.

  • Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit
    Zacks9 days ago

    Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit

    Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.

  • Dow 30 Stock Roundup: Boeing Q2 Commercial Deliveries Up Y/Y, Pfizer to Reorganize
    Zacks9 days ago

    Dow 30 Stock Roundup: Boeing Q2 Commercial Deliveries Up Y/Y, Pfizer to Reorganize

    The index enjoyed a strong week of gains, boosted by expectations of a strong second quarter earnings season.

  • Moody's10 days ago

    Merck Financial Services GmbH -- Moody's affirms Merck KGaA's Baa1 ratings

    Moody's Investors Service, ("Moody's") has today affirmed the Baa1 long-term issuer rating of Merck KGaA (Merck). Moody's has also affirmed the ratings of Merck's short term issuer, senior unsecured Medium Term Note program and junior subordinated ratings at P-2, (P)Baa1 and Baa3 respectively.

  • Merck's Keytruda Gets FDA's Priority Review for Liver Cancer
    Zacks10 days ago

    Merck's Keytruda Gets FDA's Priority Review for Liver Cancer

    The FDA grants a priority review to Merck's (MRK) label expansion filing for its key cancer drug Keytruda regarding the first-line treatment of advanced HCC.

  • Merck reduced prices of small and insignificant drugs: An...
    CNBC Videos2 days ago

    Merck reduced prices of small and insignificant drugs: An...

    Michael Yee, Jefferies managing director, sheds light on Merck reducing prices on several drugs following Pfizer and Novartis announcing they will freeze price increases for the rest of the year.

  • MARKETS: Honeywell stock pops after raising full year guidance
    Yahoo Finance Video2 days ago

    MARKETS: Honeywell stock pops after raising full year guidance

    Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after Honeywell reported second quarter adjusted earnings per share and revenue that beat Wall Street Expectations.

  • Yahoo Finance Live: Market Movers - Jul 20th, 2018
    Yahoo Finance Video3 days ago

    Yahoo Finance Live: Market Movers - Jul 20th, 2018

    Yahoo Finance's LIVE stock market coverage and analysis.